Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Enrollment progresses well in phase III FavId study in NHL

June 3, 2005

ED-B targeted therapy L19-IL2 effective in pancreatic cancer model

May 31, 2005

Norelin induces antitumor effects in patients with HDPC

May 27, 2005

Telomerase reverse transcriptase vaccination active in metastatic prostate cancer

May 26, 2005

CNTO-328 demonstrates anticancer activity in animals and humans

May 25, 2005

PRECISE trial awaits first futility analysis recommendation

May 25, 2005

Valentis gains rights to Del-1 antibody

May 24, 2005

Viragen discontinues development of IEP 11 peptide

May 24, 2005

Virulizin enhances IL-17E to propagate tumor destruction

May 23, 2005

Phase II data on MDX-010/dacarbazine combination therapy for metastatic melanoma

May 23, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...